Polycythemia Vera
📧 Sign up to get email alerts when something new happens for Polycythemia Vera.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera [Phase 2]
Phase II study of GIVINOSTAT (ITF2357) in combination with hydroxyurea in polycythemia vera has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-06-20Clinical Trial Update: A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera [Phase 1, Phase 2]
A two-part Phase 1/2 trial evaluating the safety and preliminary efficacy of givinostat in patients with polycythemia vera has completed wit…
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Pomalidomide for Myelofibrosis Patients [Phase 2]
Phase 2 clinical trial evaluating pomalidomide in myelofibrosis patients has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-05-15Clinical Trial Update: Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation [Phase 2]
Phase 2 clinical trial update evaluating a sympathicomimetic agonist in patients with myeloproliferative neoplasms carrying JAK2 mutations, …
-
CLINICAL_TRIALS trial_result · 2019-05-06Clinical Trial Update: Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) [Phase 2]
Phase 2 trial evaluating dasatinib for myeloproliferative disorders; the study has completed and results were posted in 2019.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-04-02Clinical Trial Update: Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. [Phase 3]
Phase 3 trial evaluating expanded treatment protocol of ruxolitinib in polycythemia vera patients resistant or intolerant to hydroxyurea wit…
-
CLINICAL_TRIALS trial_result · 2018-07-24Clinical Trial Update: Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) [Phase 3]
A Phase 3 randomized trial comparing pegylated interferon alfa-2a to hydroxyurea in high-risk polycythemia vera and high-risk essential thro…
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: A Study in Myeloproliferative Disorders [Phase 1]
Phase 1 study in myeloproliferative neoplasms has completed, evaluating patients with essential thrombocythemia, polycythemia vera, and prim…
-
CLINICAL_TRIALS trial_result · 2018-02-07Clinical Trial Update: Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera [Phase 2]
A Phase 2 trial of erlotinib in patients with JAK-2 V617F positive polycythemia vera has been terminated, with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-01-30Clinical Trial Update: Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera [Phase 1, Phase 2]
A safety study evaluating pegylated interferon alpha-2b in Polycythemia Vera has completed Phase 1 and Phase 2 trials.
-
FDA approval · 2017-12-18FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.
-
CLINICAL_TRIALS research · 2017-07-02Clinical Trial Update: Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders
A completed NIH-backed clinical trial examining molecular changes and biomarkers in chronic myeloproliferative disorders including polycythe…
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: Dasatinib in Polycythemia Vera [Phase 2]
A Phase 2 trial of dasatinib in polycythemia vera was terminated, with results posted.
-
CLINICAL_TRIALS trial_result · 2017-06-14Clinical Trial Update: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies [NA]
Clinical trial update for fludarabine-based conditioning prior to allogeneic transplantation in advanced hematologic malignancies; study com…
-
CLINICAL_TRIALS trial_result · 2017-04-12Clinical Trial Update: Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms [Phase 1]
Phase 1 study of LY2784544 testing alternative dosing in patients with myeloproliferative neoplasms, including polycythemia vera, essential …
-
CLINICAL_TRIALS trial_result · 2017-03-29Clinical Trial Update: Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation [Phase 1, Phase 2]
A Phase 1/2 clinical trial update reports completion of a study evaluating an investigational biological therapy in adults with advanced mye…
-
CLINICAL_TRIALS trial_result · 2017-01-11Clinical Trial Update: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) [Phase 2]
A Phase 2 trial evaluating pegylated interferon alfa-2a as salvage therapy in high-risk polycythemia vera or high-risk essential thrombocyth…
-
CLINICAL_TRIALS trial_result · 2016-11-28Clinical Trial Update: Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera [Phase 3]
Phase 3 trial comparing pegylated interferon alpha-2b with hydroxyurea in polycythemia vera has completed.
-
CLINICAL_TRIALS withdrawal · 2016-10-24Clinical Trial Update: Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis [EARLY_Phase 1]
Northwestern University’s early-phase trial of siltuximab for myelofibrosis, including primary, post-polycythemia vera, and post-essential t…
-
CLINICAL_TRIALS research · 2016-06-22Clinical Trial Update: Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features
Clinical trial update examining how often iron deficiency occurs in polycythemia vera and its relationship to disease features.
-
CLINICAL_TRIALS trial_result · 2016-05-23Clinical Trial Update: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET [Phase 2]
Phase 2 trial of the HSP90 inhibitor AUY922 in myeloproliferative neoplasms including primary myelofibrosis and MF after PV/ET was terminate…
-
CLINICAL_TRIALS withdrawal · 2016-04-20Clinical Trial Update: Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
A clinical trial (NCT02663648) evaluating a cell cycle regulatory gene study in myeloproliferative neoplasms has been withdrawn by the spons…
-
FDA approval · 2016-03-23FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)
FDA approved a supplemental application for DROXIA (hydroxyurea) filed by Waylis Therapeutics LLC.
-
CLINICAL_TRIALS trial_result · 2016-02-17Clinical Trial Update: Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients [Phase 3]
Phase 3 trial update reporting completion of a study evaluating self-administration of AOP2014 via a pen for polycythemia vera.
-
CLINICAL_TRIALS trial_result · 2016-01-26Clinical Trial Update: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera [Phase 2]
An open-label Phase 2 trial evaluating imetelstat in essential thrombocythemia or polycythemia vera has completed.